texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Plano West Research & Clinical Trials

Texas Oncology-Plano West participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Texas Oncology-Plano West (Expand)

Anal Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Biliary Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Bladder Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Breast Cancer

Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND)

A multi-center multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025) Read Moreabout Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND)

Phase: IV

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Cervical Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Colon Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Endometrial Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Esophageal Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Fallopian Tube Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Gall Bladder Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Gastric Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Head and Neck Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Hematologic

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

PATHFINDER 2 Early Detection Test

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012) Read Moreabout PATHFINDER 2 Early Detection Test

Phase: IV

Kidney Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Leukemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Liver Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Lung Cancer

STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004 Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

Phase: III

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

Phase: III

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Read Moreabout ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase: III

Ph II/III Raptor trial

Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial (NRG-LU007) Read Moreabout Ph II/III Raptor trial

Phase: II/III

Lymphomas

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Melanoma

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Myelodysplastic Syndrome

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Myelomas

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ovarian Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Pancreatic Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Peritoneal Cancer

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Prostate Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Rectal Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Renal Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Skin Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Solid Tumors

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

Phase: II

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

PATHFINDER 2 Early Detection Test

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012) Read Moreabout PATHFINDER 2 Early Detection Test

Phase: IV

Testicular Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Thyroid Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Urothelial Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Uterine Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Vulvar Cancer

DETECT-ASCEND 2 Plasma Based Test

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2) Read Moreabout DETECT-ASCEND 2 Plasma Based Test

Phase: I

Waldenström macroglobulinemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II